What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG)

scientific article published on 24 September 2009

What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG) is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1019531341
P356DOI10.1007/S00296-009-1129-7
P698PubMed publication ID19777240

P50authorJanet PopeQ48742471
P2093author name stringMurray Baron
Xiangning Fan
Canadian Scleroderma Research Group
P2860cites workMortality in systemic sclerosis: an international meta-analysis of individual patient dataQ30980001
Assessment of damage and activity in systemic sclerosisQ34090246
Systemic sclerosis: current views of its pathogenesisQ35171947
Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scaleQ35549965
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes.Q35550511
European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteriaQ35553047
Systemic sclerosis: a prototypic multisystem fibrotic disorderQ35649427
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedQ35673286
Scleroderma--clinical and pathological advancesQ35781664
Changes in causes of death in systemic sclerosis, 1972-2002Q35954516
Clinical trials in systemic sclerosis: lessons learned and outcomesQ36130965
Update on indices of disease activity in systemic sclerosisQ36760739
Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based reviewQ36961479
Factors predicting development of renal involvement in progressive systemic sclerosisQ39343777
The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over timeQ39455773
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria CommitteeQ39513167
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.Q39632069
Disease assessment indices: activity, damage and severity.Q40471904
Skin thickness and collagen content in progressive systemic sclerosis and localized sclerodermaQ41438736
What does the clinician need to improve patient care in systemic sclerosis?Q42111569
Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosisQ43537993
Severe restrictive lung disease in systemic sclerosis.Q50600064
Scleroderma: health services utilization from patients' perspective.Q51801397
Localized scleroderma severity index and global assessments: a pilot study of outcome instruments.Q53035231
Development and validation of a self-administered systemic sclerosis questionnaire (SySQ).Q53546654
Scleroderma (systemic sclerosis): classification, subsets and pathogenesisQ68330753
A disease severity scale for systemic sclerosis: development and testingQ73101147
The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosisQ73463792
How to assess musculoskeletal conditions. Assessment of disease activityQ73481988
Systemic sclerosis (scleroderma) and related disorders: clinical aspectsQ73958785
Disease severity as a predictor of outcome in sclerodermaQ77601190
Disease-specific quality indicators, guidelines and outcome measures in sclerodermaQ79898177
The scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosisQ82663613
P433issue9
P304page(s)1205-1210
P577publication date2009-09-24
P1433published inRheumatology InternationalQ15763689
P1476titleWhat is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG)
P478volume30

Reverse relations

cites work (P2860)
Q37686449Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme
Q36758822The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
Q40002833The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

Search more.